Serzone generics to remain on market
Executive Summary
FDA concludes that Bristol-Myers Squibb did not withdraw its antidepressant Serzone (nefazodone) for safety or effectiveness reasons. The distinction will allow Serzone to be listed in the "Discontinued Drug Product List" in the "Orange Book," permitting generic versions of the drug to remain on the market. The agency decision may assist Bristol in its upcoming product liability lawsuits involving Serzone...